Today's pre-market stock movers: DAL, JPM, NSTG, ATRS and more

• $Antares Pharma (ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)

• $Sierra Oncology (SRRA.US)$ +37.9% (acquired by GSK for $55 per share)

• $Amryt Pharma (AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)

• $BriaCell Therapeutics (BCTX.US)$ +6% (presents development details of Bria-OTS Platform technology)

• $Affimed NV (AFMD.US)$ +5.8% (prices offering of 22.5 mln shares of common stock at $4.00 per share)

• $Nutanix (NTNX.US)$ +5.5% (reaffirms AprQ and FY22 guidance; also names new CFO)

• $SomaLogic (SLGC.US)$ +5.3% (announces journal publication of landmark proteomics study)

• $Peloton Interactive (PTON.US)$ +2% (shareholder Blackwells Capital reiterates its call for Peloton's Board to sell the company)

• $Novavax (NVAX.US)$ +1.5% (receives Conditional Marketing Authorization from Swissmedic for its COVID-19 Vaccine)

• $Booz Allen Hamilton Holding Corp (BAH.US)$ +1.1% (upgraded to Buy from Neutral at Goldman)

• $NanoString Technologies (NSTG.US)$ -32.9% (lowers QI product and service revenue guidance),

• $Liquidia (LQDA.US)$ -13.9% (prices offering of 9,803,922 shares of its common stock at $5.10)

• $Hillman Solutions (HLMN.US)$ -10.6% (announced the upsize and pricing of the previously announced underwritten public offering of shares of the Company's common stock by certain stockholders of the Company)

• $Alpine Immune (ALPN.US)$ -8.6% (ALPN-202 monotherapy reduces tumors)

• $Osisko Gold Royalties (OR.US)$ -5.2% (provides preliminary deliveries update for QI)

• $Crinetics (CRNX.US)$ -5% (prices offering of 5,625,563 shares of its common stock at $22.22 per share

• $MaxCyte (MXCT.US)$ -3.3% (also CFO departs)

• $JPMorgan (JPM.US)$-3.51%(Earnings miss expectations)

• $PayPal (PYPL.US)$ -3.8% (PayPal CFO John Rainey to become Walmart CFO)

• $Alector (ALEC.US)$ -4.2% (initiated with a Sell at Goldman)